Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.42 |
| ▸ | HTR2C | P28335 | 10/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21019437 | 0.96 | HTR2A (0.42) | HTR2AHTR2CMAOBMAOAOPRM1 | |
| SCHEMBL21430438 | 0.86 | MAOB (0.39) | HTR2AHTR2CMAOB | |
| SCHEMBL18503383 | 0.84 | HTR2A (0.39) | HTR2AHTR2CMAOBMAOA | |
| SCHEMBL10019544 | 0.84 | HTR2A (0.42) | HTR2AHTR2CMAOBMAOAOPRM1 | |
| SCHEMBL8153366 | 0.82 | HTR2A (0.56) | HTR2AHTR2C | |
| SCHEMBL19195164 | 0.82 | HTR2A (0.36) | HTR2AHTR2CMAOBMAOA | |
| SCHEMBL10091175 | 0.81 | MAOA (0.51) | HTR2AHTR2CMAOBMAOA | |
| SCHEMBL8146281 | 0.79 | HTR2A (0.43) | HTR2AHTR2C | |
| SCHEMBL13111393 | 0.78 | HTR2A (0.33) | HTR2AHTR2C | |
| SCHEMBL18374089 | 0.77 | MAOB (0.40) | HTR2AHTR2CMAOBMAOAFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043782-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2024-07-23 | — | — | US | disclosed |
| US-12043782-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2024-07-23 | — | — | US | disclosed |
| US-11702597-B2 | Azo dye | MERCK PATENT GMBH (DE) | 2023-07-18 | — | — | US | disclosed |
| US-11702597-B2 | Azo dye | MERCK PATENT GMBH (DE) | 2023-07-18 | — | — | US | disclosed |
| US-11667845-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667845-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-20230053362-A1 | DICHROIC DYE COMPOSITION | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20230056437-A1 | AZO DYE | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-11168257-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2021-11-09 | — | — | US | disclosed |
| US-20210238481-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (JP) | 2021-08-05 | — | — | US | disclosed |
| US-10982150-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2021-04-20 | — | — | US | disclosed |
| EP-3487955-B1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-05-20 | — | — | EP | disclosed |
| WO-2020064591-A1 | AZO DYE | MERCK PATENT GMBH (DE) | 2020-04-02 | — | — | WO | disclosed |
| EP-3475389-B1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| WO-2019243216-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019238567-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-12-19 | — | — | WO | disclosed |
| US-20190241811-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190153320-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-05-23 | — | — | US | disclosed |
| WO-2018015320-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | WO | disclosed |
| US-20170045765-A1 | LCD DEVICE | DIC CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238481-A1 | LIQUID CRYSTALLINE MEDIUM | NEFM, CCNI, MYT1 | HTR2A 558/4885HTR2C 306/4885MAOB 327/4885 |
| US-11667845-B2 | Liquid crystalline medium | NEFM, CCNI, MYT1 | HTR2A 558/4885HTR2C 306/4885MAOB 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.